2.78
0.01 (0.36%)
| Penutupan Terdahulu | 2.77 |
| Jumlah Dagangan | 127,664 |
| Harga / Buku (P/B) | 6.70 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.380 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.48% |
| Nisbah Semasa (MRQ) | 8.89 |
| Aliran Tunai Operasi (OCF TTM) | -7.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.59 M |
| Pulangan Atas Aset (ROA TTM) | -39.75% |
| Pulangan Atas Ekuiti (ROE TTM) | -65.38% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Anixa Biosciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -4.0 |
| Purata | -1.75 |
|
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 5.32% |
| % Dimiliki oleh Institusi | 17.60% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Laird Norton Wetherby Trust Company, Llc | 30 Jun 2026 | 578,727 |
| D.A. Davidson & Co. | 30 Jun 2026 | 539,272 |
| Gsa Capital Partners Llp | 30 Jun 2026 | 117,465 |
| Corecap Advisors, Llc | 30 Jun 2026 | 52,020 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TITTERTON LEWIS H JR | 2.75 | - | 49,036 | 134,849 |
| Jumlah Keseluruhan Kuantiti Bersih | 49,036 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 134,849 | |||
| Purata Pembelian Keseluruhan ($) | 2.75 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TITTERTON LEWIS H JR | Pengarah | 23 Sep 2026 | Beli (+) | 49,036 | 2.75 | 134,849 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |